Physician profile
Augustine U Obinnah
NPI 1558412494
$5,500.89
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $1,376 · 2021: $2,163 · 2024: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $725.11 | 2019-2021 | |
| Novo Nordisk INC | $710.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.42 | 2019-2021 | |
| Abbvie INC. | $385.00 | 2021 | |
| Astellas Pharma US INC | $354.63 | 2019-2021 | |
| Lilly USA, LLC | $266.52 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.83 | 2019-2021 | |
| Pfizer INC. | $238.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $221.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $212.25 | 2019-2021 | |
| Allergan, INC. | $208.14 | 2019-2020 | |
| Saluda Medical Americas, INC. | $189.28 | 2024 | Evoke |
| Amgen INC. | $189.16 | 2019-2021 | |
| Glaxosmithkline, LLC. | $132.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $129.60 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $100.61 | 2024 | Prialt |
| Biohaven Pharmaceuticals, INC. | $100.25 | 2020-2021 | |
| Genentech USA, INC. | $92.52 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.54 | 2021 | |
| Sunovion Pharmaceuticals INC. | $78.02 | 2021 | |
| Eisai INC. | $67.10 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $40.01 | 2021 | |
| Medtronic Minimed, INC. | $33.30 | 2019-2020 | |
| Horizon Therapeutics Plc | $32.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.34 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.74 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.73 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.66 | 2020 | |
| Avion Pharmaceuticals | $12.80 | 2020 | |
| Abbott Laboratories | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Obinnah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.